AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

Laura McMullin, General Manager, Daiichi Sankyo UK, has been appointed Vice President of the ABPI to support UK life sciences ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most undervalued stocks. AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Chikako Shimizu Honoraria: AstraZeneca, Kyowa Hakko Kirin, Chugai Pharma, Pfizer, Daiichi Sankyo/UCB Japan, Lilly Japan Consulting or Advisory Role: Daiichi Sankyo/UCB Japan, Canon Medical System ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

DelveInsight’s Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ ...